Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis

Archives of Dermatology

Volumn 143, Issue 6, 2007, Pages 711-716

  Ziemer, Mirjana ^a   Wiesend, Christiane L ^a   Vetter, Robert ^b   Weiss, Johannes ^c   Blaschke, Sabine ^e   Norgauer, Johannes ^a   Mockenhaupt, Maja ^d,f  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

^f UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUPIRTINE; LIDOCAINE; MAGNESIUM; MEPIVACAINE; METHYLPREDNISOLONE; METOPROLOL; PARECOXIB; PREDNISOLONE; PROTON PUMP INHIBITOR; STEROID; TETRAZEPAM; VALDECOXIB;

ADULT; AGED; ARTICLE; BLISTER; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DYSPNEA; ERYTHEMA; FACE EDEMA; FEMALE; FEVER; GERMANY; HOSPITAL; HUMAN; HYPERTENSION; HYPOTENSION; ISCHIALGIA; MALAISE; MALE; ORAL MUCOSAL DISEASE; PRIORITY JOURNAL; PRURITUS; RASH; SHIVERING; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TACHYCARDIA; TOXIC EPIDERMAL NECROLYSIS; VOMITING;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DATABASES, FACTUAL; DIAGNOSIS, DIFFERENTIAL; DRUG ERUPTIONS; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; GERMANY; HOSPITALS; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; REGISTRIES; SEVERITY OF ILLNESS INDEX; STEVENS-JOHNSON SYNDROME; SULFONAMIDES;

EID: 34250764238     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.6.711     Document Type: Article

References (9)

1. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-1607.
2. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92-96.
3. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau JC; SCAR Study Group. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Arch Dermatol. 2002;138:1019-1024.
4. Waxman HA. The lessons of Vaux: drug safety and sales. N Engl J Med. 2005;352: 2576-2578.
5. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol. 1996;49:769-773.
6. Rzany B, Hering O, Mockenhaupt M, et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme majus, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 1996;135: 6-11.
7. Hering O, Mockenhaupt M, Rzany B, Schröder W, Schöpf E. The dermal type of erythema multiforme: a rare variant of Stevens-Johnson syndrome or cases of clinical misclassification? Acta Derm Venereol. 1997;77:217-218.
8. Knowles SR, Phillips EJ, Wong G, Shear NH. Serious dermatologic reaction associated with valdecoxib: report of two cases. J Am Acad Dermatol. 2004;51: 1028-1029.
9. Glasser DL, Burroughs SH. Valdecoxib-induced toxic epidermal necrolysis in a patient allergic to sulfa drugs. Pharmacotherapy. 2003;23:551-553.